New antibody shows promise in mice with Alzheimer’s disease
Scientists at UTHealth Houston have developed an agonistic antibody that reduced the amyloid pathology in mice with Alzheimer’s disease.
List view / Grid view
Scientists at UTHealth Houston have developed an agonistic antibody that reduced the amyloid pathology in mice with Alzheimer’s disease.
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
A new study has shown how tau weakens transmission across synapses in the brains of mice, providing insight into Alzheimer's.
The researchers found that augmenting NPHP5 gene rescues cilia defects in light-sensing cells derived from ciliopathy patients.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
The researchers created a chronic skull optical clearing window where they no longer needed to remove any piece of the skull.
Researchers screened biologically active small molecules, finding several compounds with the ability to induce training effects on macrophages.
A report has found that rapidly evolving R&D infrastructure will help to drive the high-content screening market forwards.
The new labelling system includes a variant of ascorbate peroxidase which is fused to another protein that is known to seek out exosomes.
A bioluminescence resonance energy transfer sensor has been developed to report changes in intracellular Ca2+ concentrations during screening.
Using screening techniques, researchers have identified the compound called AN15368 which works as an antiparasitic against Chagas disease.
A new screening study has shown that three natural compounds present in foods like green tea may be candidates for drugs that combat the coronavirus.
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
Molecular Devices has announced a collaboration with HeartBeat.bio to develop cardiac organoids for use in drug discovery.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.